Somatropin - Genotropin (Pfizer) - Complete Research Paper

1. Summary

Genotropin is a recombinant human growth hormone (rhGH, somatropin) manufactured by Pfizer for the treatment of growth disorders in children and growth hormone deficiency in adults. The drug is produced using recombinant DNA technology in Escherichia coli and contains a 191-amino acid protein identical to natural human pituitary-derived growth hormone.

FDA Approval History:

• Original approval: August 24, 1995 (pediatric GHD)
• Adult GHD: November 1997
• Prader-Willi syndrome: June 2000 (orphan drug status)
• Small for gestational age (SGA): Subsequent approval
• Turner syndrome: Subsequent approval
• Idiopathic short stature (ISS): Subsequent approval

Genotropin has been in clinical use for over 35 years and has treated more than 83,000 children worldwide. It is available in multiple dosage forms including lyophilized powder cartridges (Genotropin) and single-use prefilled syringes (Genotropin MiniQuick) for patient convenience.

Key Clinical Features:

• Drug class: Recombinant human growth hormone (somatropin)
• Molecular weight: 22,124 daltons (191 amino acids)
• Administration: Subcutaneous injection
• Half-life: 0.4 hours (IV); 3.0 hours (SC due to absorption-rate-limited elimination)
• Bioavailability: 70-90% (subcutaneous)
• Dosing frequency: Daily (typically evening)
• Generic/biosimilar: Not available in US (brand only)
• Manufacturer: Pfizer Inc. (formerly Pharmacia & Upjohn)

Mechanism Summary: Genotropin acts like natural human growth hormone by binding to GH receptors on target cells, stimulating skeletal growth, muscle growth, and protein synthesis. It normalizes IGF-I levels in growth hormone-deficient patients.

Goal Archetype Integration

FDA-Approved GH vs. Secretagogues: Critical Distinction

Genotropin is pharmaceutical recombinant human growth hormone (rhGH) - fundamentally different from GH secretagogues (sermorelin, ipamorelin, CJC-1295, MK-677).

Primary Goal Alignment

When Genotropin Makes Sense

Ideal Candidates:

1. Biochemically confirmed Adult GHD - Failed GH stimulation test (insulin tolerance test, glucagon, macimorelin)

   • Childhood-onset GHD requiring adult continuation
   • Adult-onset from pituitary disease, surgery, radiation, trauma

2. Severe symptoms despite secretagogue trial - IGF-1 remains low despite adequate GHRH/GHRP therapy

3. Non-functional pituitary - Secretagogues cannot work if somatotrophs are damaged/absent

4. Need for precise, predictable response - Direct GH allows exact dose titration

5. FDA-approved pediatric indications - GHD, Turner, PWS, SGA, ISS

Clinical Scenarios Favoring Genotropin Over Secretagogues:

When to Choose Something Else

2. Mechanism of Action

Genotropin exerts its effects through binding to the growth hormone receptor (GHR), a member of the cytokine receptor superfamily, expressed in multiple tissues throughout the body.

Primary Mechanism:

1. Receptor Binding: Somatropin binds to GH receptors on target cell membranes
2. Signal Transduction: Receptor dimerization activates JAK2 (Janus kinase 2)
3. Downstream Signaling: STAT5, MAPK, and PI3K pathways are activated
4. Gene Transcription: Growth-promoting genes are expressed
5. IGF-I Synthesis: Liver produces insulin-like growth factor-I (IGF-I/somatomedin C)

Direct Effects of Growth Hormone:

• Skeletal growth: Stimulates chondrocyte proliferation at growth plates
• Muscle growth: Promotes protein synthesis and nitrogen retention
• Fat metabolism: Enhances lipolysis and fatty acid oxidation
• Bone density: Increases bone mineral content and turnover
• Organ growth: Stimulates visceral organ development

Indirect Effects (via IGF-I):

• Linear bone growth
• Cartilage formation
• Protein synthesis
• Cell proliferation and differentiation
• Muscle development

Effects on Metabolism: | System | Effect | |---

Goal Relevance:

• Achieving normal growth in children with growth hormone deficiency
• Enhancing muscle growth and strength in adults with growth hormone deficiency
• Improving body composition by reducing fat and increasing lean mass
• Supporting growth and development in children with Prader-Willi syndrome
• Promoting linear growth in children with Turner syndrome
• Assisting in recovery and improving exercise capacity in adults with growth hormone deficiency
• Supporting growth in children born small for gestational age who haven't caught up by early childhood

-----|--------| | Protein metabolism | Increased synthesis, positive nitrogen balance | | Lipid metabolism | Enhanced lipolysis, reduced fat mass | | Carbohydrate metabolism | Insulin resistance (dose-dependent), increased hepatic glucose output | | Mineral metabolism | Increased calcium absorption, bone turnover | | Fluid/electrolyte | Sodium and water retention |

Disease-Specific Effects:

In Pediatric GHD:

• Restores linear growth velocity
• Normalizes IGF-I concentrations
• Improves body composition (lean mass vs. fat mass)

In Prader-Willi Syndrome:

• Improves linear growth
• Enhances body composition
• May improve strength and agility
• Does not treat underlying genetic disorder

In Turner Syndrome:

• Promotes linear growth despite absence of GH deficiency
• Effects mediated through IGF-I pathway
• Optimal response with early initiation

In Adult GHD:

• Improves body composition (reduces fat, increases lean mass)
• Enhances exercise capacity
• Improves bone mineral density
• May improve quality of life measures

3. FDA-Approved Indications

Pediatric Indications:

Adult Indications:

Diagnostic Requirements for Adult GHD: Patients with childhood-onset GHD should be retested and biochemically confirmed as GH-deficient before continuation of therapy with Genotropin at the recommended adult dosage.

Regulatory Status:

Orphan Drug Status:

• Prader-Willi syndrome (granted June 2000)

4. Dosing and Administration

General Principles:

• Dosage and schedule should be individualized based on patient response
• Weekly dose should be divided into 6-7 daily subcutaneous injections
• Preferably administered in the evening (mimics physiologic secretion)
• Rotate injection sites to prevent lipoatrophy

Pediatric Dosing:

Special Considerations - SGA:

• Very short children (height SDS <-3) may benefit from higher initial doses (up to 0.48 mg/kg/week)
• Reduce dose gradually toward 0.24 mg/kg/week if substantial catch-up growth observed
• Younger SGA children (<4 years) with less severe short stature may start at lower doses (0.24 mg/kg/week)

Adult GHD Dosing:

Weight-Based Regimen:

• Starting dose: Not more than 0.04 mg/kg/week
• May increase at 4-8 week intervals
• Maximum: 0.08 mg/kg/week

Non-Weight-Based Regimen (Preferred):

• Starting dose: 0.2 mg/day (range 0.15-0.30 mg/day)
• Increase gradually every 1-2 months by 0.1-0.2 mg/day increments
• Maximum: 1.33 mg/day
• Maintenance dose: Individualized based on IGF-I response

Dose Adjustments:

Administration:

• Subcutaneous injection only
• Preferred sites: Thigh, abdomen, buttock, upper arm
• Rotate injection sites
• Evening administration preferred
• Available in cartridges (Genotropin) and prefilled single-use (MiniQuick)

Product Presentations:

Age-Stratified Dosing (Adult GHD)

Rationale for Age-Based Approach: Unlike secretagogues that rely on pituitary function, rhGH dosing must account for age-related changes in GH sensitivity, metabolic rate, and side effect risk. Older patients are MORE sensitive to GH effects and MORE prone to side effects, requiring lower starting doses.

Weight-Based vs. Non-Weight-Based Dosing:

Age-Specific Adult GHD Dosing (Non-Weight-Based - Preferred):

Age-Specific Weight-Based Dosing (Alternative):

Why Elderly Need Lower Doses:

Sex-Specific Considerations:

Females:

• Oral estrogen increases GH-binding protein → reduced free GH → may need 25-50% higher doses
• Transdermal estrogen has less effect on GH binding
• Postmenopausal women often start at lower end of range
• Monitor for fluid retention (breast tenderness, bloating)

Males:

• Generally respond more predictably
• Testosterone therapy is synergistic (both enhance body composition)
• Monitor for gynecomastia (GH + testosterone aromatization)

Obesity Dosing:

• Non-weight-based dosing STRONGLY preferred in obesity
• Weight-based dosing leads to overdose and excessive side effects
• Start at low fixed dose regardless of weight
• Titrate based on IGF-1 response, not weight

Conversion Reference:

*Approximate; 1 mg somatropin ≈ 3 IU (varies slightly by manufacturer)

5. Pharmacokinetics

Absorption:

• Route: Subcutaneous injection
• Bioavailability: 70-90% (absolute)
• Tmax: Variable based on injection site and volume
• Absorption rate: Rate-limiting step determining observed half-life

Distribution:

• Volume of distribution: Not formally characterized for Genotropin
• Distributes to liver, kidney, muscle, bone, and other tissues
• Does not cross blood-brain barrier significantly

Metabolism:

• Primary site: Liver and kidney (classical protein catabolism)
• Cleaved into smaller peptides and amino acids
• Breakdown products returned to systemic circulation from renal cells
• No significant CYP450 involvement

Elimination:

• Terminal half-life (IV): 0.4 hours
• Terminal half-life (SC): 3.0 hours (absorption-rate limited)
• Metabolic half-life: 20-30 minutes
• Clearance (SC): 0.3 ± 0.11 L/hr/kg (adult GHD patients)

Comparison of Routes:

Special Populations:

Pediatric vs. Adult: The pharmacokinetics of Genotropin are similar in GHD pediatric and adult patients.

Gender: Absolute bioavailability is similar in males and females following subcutaneous administration.

Renal Impairment:

• Reduced clearance expected
• No specific dose recommendations; use with caution

Hepatic Impairment:

• Reduced clearance expected (liver is major site of catabolism)
• No specific dose recommendations; use with caution

Obesity:

• May have altered distribution
• Non-weight-based dosing preferred to avoid overdosing

6. Side Effects and Adverse Reactions

Clinical Trial Safety Data: In clinical trials with Genotropin in 1,145 GHD adults, adverse events were generally mild to moderate and related to fluid retention.

Common Adverse Events by Population:

Adults with GHD:

These events were reported early during therapy and tended to be transient and/or responsive to dosage reduction.

Pediatric Patients with GHD:

• Injection site reactions (pain, burning, fibrosis, nodules, rash, inflammation, pigmentation, bleeding)
• Lipoatrophy
• Headache
• Hematuria
• Hypothyroidism
• Mild hyperglycemia

Prader-Willi Syndrome:

• Edema
• Aggressiveness
• Arthralgia
• Benign intracranial hypertension
• Hair loss
• Headache
• Myalgia

Turner Syndrome:

• Respiratory illnesses (influenza, tonsillitis, otitis, sinusitis)
• Joint pain
• Urinary tract infection

Idiopathic Short Stature:

• Upper respiratory tract infections
• Influenza, tonsillitis, nasopharyngitis
• Gastroenteritis
• Headaches
• Increased appetite
• Pyrexia
• Fracture
• Altered mood
• Arthralgia

Long-Term Safety Data (Post-Trial Extension):

Diabetes Mellitus:

• 12 of 3,031 patients (0.4%) developed diabetes during Genotropin treatment
• All 12 patients had predisposing factors (elevated HbA1c, marked obesity)

Carpal Tunnel Syndrome:

• 61 of 3,031 patients (2%) developed symptoms
• 52 patients improved with dose reduction or treatment interruption
• 9 patients required surgery

Serious Adverse Reactions:

Pediatric-Specific Serious Events:

• Slipped capital femoral epiphysis
• Legg-Calvé-Perthes disease (avascular necrosis)
• Pancreatitis (rare; girls with Turner syndrome at higher risk)
• Benign intracranial hypertension (pseudotumor cerebri)

Post-Marketing Reports:

• Headaches (children and adults)
• Gynecomastia (children)
• Significant diabetic retinopathy
• New-onset type 2 diabetes mellitus
• Injection site lipohypertrophy

Malignancy Considerations: Long-term surveillance suggests no increased risk of new primary cancers; however, patients with history of malignancy should be monitored.

7. Drug Interactions - Comprehensive

Understanding drug interactions is critical for safe and effective rhGH therapy. Unlike secretagogues, direct GH administration has more pronounced metabolic effects requiring careful medication management.

7.1 Diabetes Medications - CRITICAL INTERACTION

Interaction Severity: MODERATE TO HIGH

Genotropin significantly antagonizes insulin action, requiring careful management in diabetic patients. This effect is MORE pronounced than with GH secretagogues.

Clinical Protocol for Diabetic Patients Starting Genotropin:

1. Baseline HbA1c and fasting glucose REQUIRED
2. Start GH at LOWEST dose (0.1 mg/day regardless of age)
3. Increase glucose monitoring to 4x daily for first 4 weeks
4. Anticipate 15-30% increase in insulin requirements
5. Titrate GH slower than non-diabetics (q8-12 weeks)
6. Check HbA1c at 3 months and 6 months
7. Consider endocrinology co-management

When to AVOID Genotropin in Diabetics:

• Uncontrolled diabetes (HbA1c >9%)
• Active proliferative diabetic retinopathy
• Diabetic foot ulcers (may impair healing despite GH)
• History of diabetic ketoacidosis

7.2 Glucocorticoids - SIGNIFICANT INTERACTION

Interaction Severity: MODERATE TO HIGH

Glucocorticoids and GH have opposing effects on multiple metabolic pathways. Concurrent use requires careful management.

Mechanism of Interaction:

• Glucocorticoids suppress GH secretion (less relevant for exogenous GH)
• Glucocorticoids antagonize GH action at peripheral tissues
• Both increase hepatic gluconeogenesis (additive hyperglycemic effect)
• Glucocorticoids are catabolic; GH is anabolic (opposing effects on muscle)

Critical Consideration - Adrenal Insufficiency: Genotropin may UNMASK central adrenal insufficiency by:

• Increasing 11β-HSD1 activity (converts cortisone → cortisol)
• Initially may see DECREASED cortisol availability
• Patients with marginal adrenal reserve may become symptomatic

Recommendation: Check morning cortisol at baseline and 8-12 weeks after GH initiation.

7.3 Thyroid Medications

Interaction Severity: MODERATE

GH and thyroid hormones are intimately connected. GH therapy frequently reveals or exacerbates thyroid dysfunction.

Monitoring Protocol:

• Baseline: TSH, free T4 (consider free T3)
• 8-12 weeks after GH initiation: Repeat thyroid panel
• Then every 6-12 months

Clinical Pearl: Inadequate thyroid replacement is a common cause of poor GH response. Always optimize thyroid before concluding GH is ineffective.

7.4 Sex Steroids

Estrogen:

Testosterone:

7.5 Other Critical Drug Interactions

7.6 Drug-Lab Test Interactions

7.7 Drug-Food Interactions

8. Contraindications

Absolute Contraindications:

1. Active malignancy: Should not be used in patients with active cancer

   • Discontinue somatropin if evidence of recurrent activity

2. Critical illness: Contraindicated in patients who are critically ill due to:

   • Complications following open heart surgery
   • Abdominal surgery
   • Multiple accidental trauma
   • Acute respiratory failure
   • (Increased mortality demonstrated in clinical trials)

3. Prader-Willi syndrome with severe obesity or respiratory impairment:

   • Reports of sudden death in PWS patients with one or more risk factors:
     • Severe obesity
     • History of upper airway obstruction or sleep apnea
     • Respiratory infections
   • Males may be at greater risk

4. Closed epiphyses: For growth promotion indications, do not use if growth plates have fused

5. Hypersensitivity: Known hypersensitivity to somatropin or any excipient

6. Active proliferative or severe non-proliferative diabetic retinopathy

Relative Contraindications/Precautions:

Prader-Willi Syndrome - Specific Requirements: Before initiating therapy in PWS patients:

• Evaluate for upper airway obstruction
• Assess for sleep apnea
• Control weight
• Monitor for respiratory infections
• Interrupt treatment if signs of upper airway obstruction develop

9. Special Populations

Pediatric Use:

• Safety and efficacy established for approved pediatric indications
• Dosing specific to each indication
• Monitor growth response and adjust dose accordingly
• Watch for slipped capital femoral epiphysis (hip/knee pain, limping)
• Regular monitoring of scoliosis in at-risk populations

Geriatric Use:

• Clinical trials included limited numbers of subjects ≥65 years
• Elderly patients may be more sensitive to somatropin effects
• Use lower starting doses
• Use smaller dose increments
• Monitor more frequently for adverse effects

Pregnancy:

• FDA Pregnancy Category: Not formally categorized under new labeling
• No adequate human studies
• Animal studies: No evidence of teratogenicity at appropriate doses
• Use only if clearly needed and benefits outweigh risks

Lactation:

• Unknown if excreted in human milk
• Caution advised if used during breastfeeding
• Consider developmental benefits of breastfeeding vs. need for treatment

Renal Impairment:

• No formal studies in renal impairment
• Reduced clearance expected
• Chronic kidney disease (CKD) patients may receive somatropin
• Maintain adequate nutritional status in CKD

Hepatic Impairment:

• No formal studies in hepatic impairment
• Liver is major site of GH catabolism
• Reduced clearance expected; use caution

Obesity:

• Obese patients more likely to experience adverse effects
• Non-weight-based dosing recommended
• Higher risk of carpal tunnel syndrome
• Monitor carefully for fluid retention

Diabetes and Prediabetes:

• May worsen glucose tolerance
• Monitor glucose levels
• May require initiation or adjustment of antidiabetic therapy
• Consider risk-benefit carefully

Turner Syndrome:

• Higher risk of pancreatitis compared to other indications
• Monitor for cardiovascular abnormalities
• Otitis media common; monitor hearing
• May have increased scoliosis risk

Prader-Willi Syndrome:

• See contraindications regarding severe obesity/respiratory issues
• Evaluate sleep apnea before and during treatment
• Monitor weight carefully
• Watch for respiratory infections

10. Monitoring Parameters

Baseline Assessment:

Ongoing Monitoring:

Growth Parameters (Pediatric):

Laboratory Monitoring:

Clinical Monitoring:

Dose Adjustment Triggers:

• IGF-I consistently above normal range: Decrease dose
• IGF-I below normal range: Consider dose increase
• Adverse effects: Consider dose reduction
• Poor growth response: Evaluate compliance, thyroid function, nutrition

Stopping Criteria (Pediatric Growth Indications):

• Near-adult height achieved
• Growth velocity <2 cm/year after pubertal growth
• Bone age indicating epiphyseal fusion
• Patient/family preference

11. Cost and Availability

Pricing (United States, 2024-2025):

Annual Cost Estimates:

• Typical pediatric patient: $20,000-$40,000/year (dose-dependent)
• Adult GHD patient: $15,000-$30,000/year (dose-dependent)

Generic/Biosimilar Status:

• Generic: Not available (Genotropin is brand-only in US)
• Biosimilar: No FDA-approved biosimilar in US as of 2024
• International: Biosimilars available in some markets (Europe)
• Future outlook: Biosimilar competition expected to emerge 2025-2028

Insurance Coverage:

• Medicare Part B: May cover for specific diagnoses
• Medicare Part D: Limited coverage
• Private insurance: Variable; often requires prior authorization
• Step therapy: May be required (try other brands first)

Patient Assistance Programs:

Eligibility Restrictions:

• State and federal beneficiaries (Medicare, Medicaid) NOT eligible for copay programs
• Income-based eligibility for patient assistance programs

Supply Considerations (2024-2025):

• Pfizer scaled up production 3.5× in 2023 vs. 2022
• Market disruptions have caused supply constraints
• Long hold times reported for Pfizer Bridge Program
• No anticipated long-term supply disruption

International Availability:

• Available in 90+ countries
• Brand names may vary by country
• Pricing varies significantly by market

Product Presentations:

12. Clinical Evidence Summary

Pivotal Clinical Trials:

Pediatric GHD:

• Numerous controlled trials demonstrating significant improvement in height velocity
• Mean height velocity increases from ~4 cm/year to 10+ cm/year in first year
• Long-term studies showing improved adult height outcomes

Adult GHD:

• Clinical trials in 1,145 adults demonstrating efficacy
• Improvements in body composition (increased lean mass, decreased fat mass)
• Enhanced quality of life measures
• Improved exercise capacity

Prader-Willi Syndrome: Key findings leading to FDA approval (2000):

• Improved linear growth
• Favorable changes in body composition
• Maintained or improved respiratory function when properly monitored
• No worsening of behavioral issues with appropriate patient selection

Turner Syndrome:

• Multiple trials demonstrating improved adult height
• Height gains of 5-8 cm above predicted adult height
• Optimal response with early initiation and adequate dosing
• May continue through transition if growth potential remains

Small for Gestational Age (SGA):

• Significant improvement in height SDS
• Many patients achieve normal height range
• Higher doses (up to 0.48 mg/kg/week) may be needed
• Best response in younger children

Idiopathic Short Stature (ISS):

• Modest but significant improvement in adult height (mean +4-5 cm)
• Response varies considerably among individuals
• Predictors of response studied but not definitive

Long-Term Safety Data: From extension studies (3,031 patients):

• Diabetes incidence: 0.4% (all with predisposing factors)
• Carpal tunnel syndrome: 2%
• No increased cancer risk above background rates
• Generally well-tolerated with dose adjustment

IGF-I Normalization:

• Treatment normalizes IGF-I levels in GHD patients
• IGF-I used as biomarker for dose optimization
• Maintenance within age-appropriate normal range recommended

13. Comparison with Alternatives

Comparison of FDA-Approved Somatropin Products:

Key Differentiators for Genotropin:

Comparison by Key Criteria:

Device Convenience:

• Norditropin FlexPro: Pre-filled pen, room temp stable (best convenience)
• Genotropin MiniQuick: Pre-filled, single-use (no refrigeration after dispensing)
• Others: Require reconstitution or refrigeration

Cost:

• Omnitrope: Lowest cost (biosimilar)
• Zomacton: Lower cost branded option
• Genotropin: Mid-to-higher tier pricing

Indications: All FDA-approved somatropin products share similar indications; minor label differences exist.

When to Choose Genotropin:

1. Need for precise dosing (MiniQuick range)
2. Patient preference for single-use devices
3. Access to Pfizer assistance programs
4. Established relationship with Genotropin
5. Travel convenience (MiniQuick does not require refrigeration after dispensing)

Switching Considerations:

• All somatropin products are therapeutically equivalent
• Switching may be driven by insurance formulary
• Dosing is similar across products
• Device training required when switching

14. Storage and Handling

Storage Conditions:

Genotropin Cartridges (5 mg, 12 mg):

Genotropin MiniQuick:

MiniQuick advantage: Can be stored at room temperature before use for up to 3 months

General Storage Guidelines:

• Protect from light
• Do NOT freeze
• Do not use if solution is cloudy or contains particles
• Keep out of reach of children

Reconstitution Instructions (Cartridge):

1. Insert cartridge into Genotropin Pen or Genotropin Mixer
2. Follow device instructions for reconstitution
3. Gently swirl; do not shake
4. Inspect for clarity before use

Reconstitution Instructions (MiniQuick):

1. Remove from package
2. Push plunger to release diluent into powder chamber
3. Gently swirl 5-10 times
4. Inspect for clarity
5. Inject within 24 hours

Handling Precautions:

• Wash hands before handling
• Clean injection site with alcohol
• Rotate injection sites
• Dispose of used devices in sharps container
• Do not reuse needles

Travel Guidelines:

• Keep in insulated cooler if refrigeration required
• MiniQuick: Can travel at room temperature (up to 3 months)
• Carry letter from physician for international travel
• Do not expose to extreme temperatures

Disposal:

• Dispose of used devices in FDA-cleared sharps container
• Never dispose in household trash
• Follow local regulations for pharmaceutical waste

15. References

1. FDA Genotropin Prescribing Information. Pfizer Inc. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020280s090lbl.pdf

2. Pfizer Medical. GENOTROPIN (somatropin) Product Information. Available at: https://www.pfizermedical.com/genotropin

3. Drug Approval Package: Genotropin (Somatropin [rDNA origin]) NDA #20-280. FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-280S031_Genotropin.cfm

4. GENOTROPIN Official Site (Pfizer). Available at: https://www.genotropin.com/

5. Drugs.com. Genotropin: Uses, Dosage, Side Effects, Warnings. Available at: https://www.drugs.com/genotropin.html

6. GoodRx. Genotropin 2025 Prices, Coupons & Savings Tips. Available at: https://www.goodrx.com/genotropin

7. DrugBank. Somatotropin: Uses, Interactions, Mechanism of Action. Available at: https://go.drugbank.com/drugs/DB00052

8. DailyMed. GENOTROPIN- somatropin kit. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765

9. Medscape. Genotropin, Humatrope (somatropin) dosing, indications, interactions, adverse effects. Available at: https://reference.medscape.com/drug/genotropin-somatropin-342860

10. Current Status of Biosimilar Growth Hormone. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC2777019/

11. FDA. Drug Enforcement Administration. Human Growth Hormone Overview. Available at: https://www.deadiversion.usdoj.gov/drug_chem_info/hgh.pdf

12. Pfizer Bridge Program Information. Available via Pfizer RxPathways.

Document compiled from FDA prescribing information, manufacturer resources, and clinical literature. Last updated: December 2024.

Status: PAPER 68 OF 76 COMPLETE

Next Paper: #69 - Somatropin (Humatrope)